Search

The increasing number of cancer patients, together with the side effects of current chemical treatments have encouraged the exploration of the potential of Iranian medicinal plants as a rich source of anticancer compounds. In the current review, 114 medicinal plant species grown in Iran were selected and their major constituents, animal or cell targets, as well as possible anticancer mechanisms, were ascertained through searching pertinent keywords in the Scientific Information Database (SID), IranMedex, PubMed, Medline, Google Scholar, Science Direct, Web of Knowledge and Scopus databases. Of the 114 species (with more emphasis on Asteraceae, Lamiaceae and Fabaceae as major plant families in Iran) that were reviewed, some were endemic plants of Iran, with others found in other countries. Besides valuable and well-known anticancer plants such as Taxus baccata and Catharanthus roseus, other species were included. Several compounds of these plants, such as organo-sulfur compounds, terpenoids, polyphenols, alkaloids, saponins, phenylethanoids, coumarins and polysaccharides have been proposed to exhibit anticancer effects. In general, apoptosis, cytotoxicity, cell cycle arrest, mitochondrial suppression, reductiob of DNA damage, vital enzyme inhibition and/or blocking angiogenesis were considered as the proposed mechanisms for the anticancer potential of the studied plants. Investigating the bioactive anticancer components of Iranian medicinal plants, especially the endemic species, seems to be beneficial for achieving novel potential anticancer drugs that are better equipped to fight cancer. [Display omitted] • Besides well-known plants, there are numerous endemic species with anticancer potentials in Iran • The anticancer effects are mostly due to organo-sulfur compounds, terpenoids, polyphenols and alkaloids. • Inducing apoptosis, cell cycle arrest, oxidative stress, enzymes' inhibition and blocking angiogenesis are the main anticancer activities. • Investigating Iranian medicinal plants can be useful for achieving new active anticancer medication. [ABSTRACT FROM AUTHOR]

Background: Some countries have used opioid agonist medications other than methadone and buprenorphine as a strategy to increase treatment diversity. In Iran and other countries where opium use is common and culturally tolerated, opium tincture (OT) has gained growing popularity and been approved to treat opioid use disorder (OUD). Given the increasing interest in this intervention, we conducted a systematic review of the literature to evaluate the safety and efficacy of OT-assisted treatment for OUD.Methods: We systematically searched international (MEDLINE, Embase, CINAHL, PsychInfo, Google Scholar, and clinicaltrials.gov) and Iranian (Scientific Information Database (SID), Iranmedex, IranDoc, digital library of Iran's Drug Control Headquarters and the Iranian Registry for Clinical Trials) databases on November 04, 2020 without any language or publication date limitations. Two reviewers screened the titles, abstracts, and full-text of the retrieved records to find clinical trials or observational studies that assessed the safety and efficacy of OT-assisted treatment for OUD.Results: We screened 1301 records and included 21 unique studies on assisted withdrawal (n = 5), maintenance (n = 9), and gradual dose reduction (n = 7) treatment regimens. Most studies included men and people with opium use disorder. We found only six randomized controlled trials (RCT). Our results showed that OT-assisted treatment is associated with comparable outcomes with methadone treatment in both assisted withdrawal and maintenance treatment regimens. We also found promising results for using gradual dose reduction regimen of OT-assisted treatment from observational studies. The overall quality of scientific evidence was low due to the limited number RCT and high risk of bias in the included studies.Conclusions: The body of evidence supporting the safety and efficacy of OT-assisted treatment in assisted withdrawal, maintenance, and gradual dose reduction regimens is limited but somewhat promising, in particular among people with opium use disorder. Our review calls for higher-quality studies to investigate the comparative efficacy of these treatment methods with standard pharmacotherapies for OUD. [ABSTRACT FROM AUTHOR]

Introduction: Buprenorphine maintenance treatment (BMT) is widely used in Iran, and its use is growing continuously. We reviewed studies on buprenorphine use, non-prescribed use, use disorder and treatment-seeking for it, buprenorphine-associated poisoning, and mortality in Iran in the current systematic review.Methods: An Iranian database (Scientific Information Database; SID) and three International electronic databases (PubMed, Scopus, and Web of Science) were searched for publications up to August 2020 for the relevant data. Opportunistic methods (Contact with experts and backward citation tracking) were also used for this purpose. Identified records were screened for eligibility criteria, and data of included studies were extracted. For context, the trend of BMT in the country was also examined.Results: Ten studies were found on the prevalence of non-prescribed buprenorphine use, seven were on the regular use and use disorder, and two studies on buprenorphine poisoning. The last 12-month prevalence of non-prescribed use was lower than 0.5 % in the general population, university, and high school students. The indicator was 2.5 % among persons who use drugs in a 2018 national study. The proportion of buprenorphine poisoning was 4.9 % among all illicit substance poisoning cases admitted to a hospital. The proportion of buprenorphine poisoning cases among all acute pediatric drug poisoning cases increased from 1.2 % to 2.5 % in a 3-year study.Conclusion: Despite the expansion of BMT in Iran in the last decade, the adverse health consequences associated with buprenorphine are infrequent, when compared to other opioids used in Iran, suggesting the safety of BMT for future expansion. [ABSTRACT FROM AUTHOR]